BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cholangiocarcinoma Working Group. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment. Dig Liver Dis 2020;52:1430-42. [PMID: 32952071 DOI: 10.1016/j.dld.2020.08.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Granata V, Fusco R, De Muzio F, Cutolo C, Grassi F, Brunese MC, Simonetti I, Catalano O, Gabelloni M, Pradella S, Danti G, Flammia F, Borgheresi A, Agostini A, Bruno F, Palumbo P, Ottaiano A, Izzo F, Giovagnoni A, Barile A, Gandolfo N, Miele V. Risk Assessment and Cholangiocarcinoma: Diagnostic Management and Artificial Intelligence. Biology 2023;12:213. [DOI: 10.3390/biology12020213] [Reference Citation Analysis]
2 Ohaegbulam KC, Koethe Y, Fung A, Mayo SC, Grossberg AJ, Chen EY, Sharzehi K, Kardosh A, Farsad K, Rocha FG, Thomas CR, Nabavizadeh N. The multidisciplinary management of cholangiocarcinoma. Cancer 2023;129:184-214. [PMID: 36382577 DOI: 10.1002/cncr.34541] [Reference Citation Analysis]
3 Granata V, Fusco R, Setola SV, Simonetti I, Picone C, Simeone E, Festino L, Vanella V, Vitale MG, Montanino A, Morabito A, Izzo F, Ascierto PA, Petrillo A. Immunotherapy Assessment: A New Paradigm for Radiologists. Diagnostics (Basel) 2023;13. [PMID: 36673112 DOI: 10.3390/diagnostics13020302] [Reference Citation Analysis]
4 Cutolo C, Fusco R, Simonetti I, De Muzio F, Grassi F, Trovato P, Palumbo P, Bruno F, Maggialetti N, Borgheresi A, Bruno A, Chiti G, Bicci E, Brunese MC, Giovagnoni A, Miele V, Barile A, Izzo F, Granata V. Imaging Features of Main Hepatic Resections: The Radiologist Challenging. J Pers Med 2023;13. [PMID: 36675795 DOI: 10.3390/jpm13010134] [Reference Citation Analysis]
5 Granata V, Fusco R, Setola SV, Galdiero R, Maggialetti N, Silvestro L, De Bellis M, Di Girolamo E, Grazzini G, Chiti G, Brunese MC, Belli A, Patrone R, Palaia R, Avallone A, Petrillo A, Izzo F. Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence. Cancers (Basel) 2023;15. [PMID: 36672301 DOI: 10.3390/cancers15020351] [Reference Citation Analysis]
6 Dewald CLA, Becker LS, Meine TC, Maschke SK, Wacker FK, Saborowski A, Vogel A, Hinrichs JB. New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option. Clin Exp Metastasis 2023;40:95-104. [PMID: 36417096 DOI: 10.1007/s10585-022-10193-4] [Reference Citation Analysis]
7 Xiao M, Wang D, Lin GL, Lin X, Tao LY, Li QY. Safely Modified Laparoscopic Liver Resection for Segment VI and/or VII Hepatic Lesions Using the Left Lateral Decubitus Position. Int J Gen Med 2022;15:6691-9. [PMID: 36034184 DOI: 10.2147/IJGM.S376919] [Reference Citation Analysis]
8 De Muzio F, Grassi F, Dell’aversana F, Fusco R, Danti G, Flammia F, Chiti G, Valeri T, Agostini A, Palumbo P, Bruno F, Cutolo C, Grassi R, Simonetti I, Giovagnoni A, Miele V, Barile A, Granata V. A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls. Diagnostics 2022;12:1655. [DOI: 10.3390/diagnostics12071655] [Reference Citation Analysis]
9 Yuan ZB, Fang HB, Feng QK, Li T, Li J. Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy: A retrospective study. World J Gastroenterol 2022; 28(15): 1574-1587 [DOI: 10.3748/wjg.v28.i15.1574] [Reference Citation Analysis]
10 Xing H, Tan B, Yang C, Zhang M. Incidence Trend and Competing Risk Analysis of Patients With Intrahepatic Cholangiocarcinoma: A Population-Based Study. Front Med (Lausanne) 2022;9:846276. [PMID: 35433765 DOI: 10.3389/fmed.2022.846276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Granata V, Fusco R, Belli A, Borzillo V, Palumbo P, Bruno F, Grassi R, Ottaiano A, Nasti G, Pilone V, Petrillo A, Izzo F. Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma. Infect Agents Cancer 2022;17. [DOI: 10.1186/s13027-022-00429-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Qin L, Kuai J, Yang F, Yang L, Sun P, Zhang L, Li G. Selected by bioinformatics and molecular docking analysis, Dhea and 2–14,15-Eg are effective against cholangiocarcinoma. PLoS ONE 2022;17:e0260180. [DOI: 10.1371/journal.pone.0260180] [Reference Citation Analysis]
13 Bagante F, Tripepi M, Guglielmi A, Iacono C, Ruzzenente A. Major Hepatic Resection for Peri-hilar Biliary Cancers. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_56] [Reference Citation Analysis]
14 Manzia TM, Parente A, Lenci I, Sensi B, Milana M, Gazia C, Signorello A, Angelico R, Grassi G, Tisone G, Baiocchi L. Moving forward in the treatment of cholangiocarcinoma. World J Gastrointest Oncol 2021; 13(12): 1939-1955 [DOI: 10.4251/wjgo.v13.i12.1939] [Reference Citation Analysis]
15 Liu Y, Li G, Lu Z, Wang T, Yang Y, Wang X, Liu J. Effect of vascular resection for perihilar cholangiocarcinoma: a systematic review and meta-analysis. PeerJ 2021;9:e12184. [PMID: 34631316 DOI: 10.7717/peerj.12184] [Reference Citation Analysis]
16 Sarcognato S, Sacchi D, Fassan M, Fabris L, Cadamuro M, Zanus G, Cataldo I, Capelli P, Baciorri F, Cacciatore M, Guido M. Cholangiocarcinoma. Pathologica 2021;113:158-69. [PMID: 34294934 DOI: 10.32074/1591-951X-252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]